What is the role of the receptor for advanced glycation end products–ligand axis in liver injury?

Multiligand receptor for advanced glycation end products (RAGE) is expressed in a wide variety of tissues, including the liver. Interactions with its ligands lead to cellular activation and thus prolonged inflammation and apoptosis. RAGE also exists in a soluble, truncated isoform called soluble RAGE, which has the same ligand‐binding specificity as membrane‐RAGE; acting as decoy, it can contribute to the removal/neutralization of circulating ligands and the resultant reduction of signaling pathway activation. Experimental and clinical studies have highlighted the idea that the RAGE‐ligand axis is involved in the development of liver fibrosis, inflammation, and regeneration after a massive injury and in the setting of liver transplantation. The involvement of the RAGE‐ligand axis in vascular disease, diabetes, cancer, and neurodegeneration is well established, but it still needs to be clarified in the setting of liver diseases. We present a review of the recent literature on this receptor in surgical and clinical settings involving the liver, and we highlight the open issues and possible directions of future research. Liver Transpl 17:633‐640, 2011. © 2011 AASLD.

[1]  Their Families,et al.  LONG-TERM OUTCOMES , 2013 .

[2]  F. Chiarelli,et al.  What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children? , 2011, Antioxidants & redox signaling.

[3]  M. Demir,et al.  Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment? , 2010, Viral immunology.

[4]  M. Menger,et al.  Oxidative stress-associated rise of hepatic protein glycation increases inflammatory liver injury in uncoupling protein-2 deficient mice , 2010, Laboratory Investigation.

[5]  M. Chatzopoulou,et al.  RAGE: a multi-ligand receptor unveiling novel insights in health and disease. , 2010, Current medicinal chemistry.

[6]  A. V. Pileggi,et al.  Receptor for Advanced Glycation End Products in Donor Lungs Is Associated with Primary Graft Dysfunction After Lung Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  L. V. van Grunsven,et al.  Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. , 2010, Journal of hepatology.

[8]  S. Klein,et al.  Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications , 2010, Hepatology.

[9]  D. Schuppan,et al.  Role of the receptor for advanced glycation end products in hepatic fibrosis. , 2009, World journal of gastroenterology.

[10]  C. Deutschman,et al.  Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. , 2009, American journal of respiratory and critical care medicine.

[11]  E. Assenat,et al.  Long‐term outcomes of liver transplantation: Diabetes mellitus , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  M. Grompe,et al.  Stem cells and liver regeneration. , 2009, Gastroenterology.

[13]  O. O. Gul,et al.  Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. , 2009, Clinical biochemistry.

[14]  J. Emond,et al.  Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury. , 2009, Journal of hepatology.

[15]  H. Rauvala,et al.  High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[16]  Tiantai Zhang,et al.  Advanced glycation end products serve as ligands for lectin‐like oxidized low‐density lipoprotein receptor‐1(LOX‐1): biochemical and binding characterizations assay , 2008, Cell biochemistry and function.

[17]  P. Saftig,et al.  A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  M. Tai,et al.  High-mobility group box 1 protein activates hepatic stellate cells in vitro. , 2008, Transplantation proceedings.

[19]  N. Zhu,et al.  Specific siRNA Targeting the Receptor for Advanced Glycation End Products Inhibits Experimental Hepatic Fibrosis in Rats , 2008, International journal of molecular sciences.

[20]  G. Basta Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. , 2008, Atherosclerosis.

[21]  K. Chayama,et al.  Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells , 2008, Journal of Gastroenterology.

[22]  S. Natsugoe,et al.  Annals of Surgical Oncology 15(3):923–933 DOI: 10.1245/s10434-007-9698-8 A Novel Function of the Receptor for Advanced Glycation , 2022 .

[23]  M. Rosengart,et al.  HMGB1 release induced by liver ischemia involves Toll-like receptor 4–dependent reactive oxygen species production and calcium-mediated signaling , 2007, The Journal of experimental medicine.

[24]  K. Chayama,et al.  Elevated levels of serum advanced glycation end products in patients with non‐alcoholic steatohepatitis , 2007, Journal of gastroenterology and hepatology.

[25]  A. Arroliga,et al.  Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[26]  U. Klotz,et al.  Unchanged serum levels of advanced glycation endproducts in patients with liver disease , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

[27]  R. Abbate,et al.  Circulating levels of Nɛ-(carboxymethyl)lysine are increased in systemic sclerosis , 2007 .

[28]  K. Herold,et al.  Blockade of RAGE Suppresses Alloimmune Reactions In Vitro and Delays Allograft Rejection in Murine Heart Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  U. Klotz,et al.  Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease , 2006, Journal of Clinical Pathology.

[30]  N. Ohmori,et al.  Role of antinuclear antibodies in experimental and clinical liver transplantation. , 2006, Transplantation proceedings.

[31]  E. Ferrannini,et al.  Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. , 2006, The Journal of clinical endocrinology and metabolism.

[32]  Takafumi Yoshida,et al.  Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation , 2006, Diabetologia.

[33]  R. Tilton,et al.  Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  J. Emond,et al.  Blockade of the receptor for advanced glycation end products attenuates acetaminophen‐induced hepatotoxicity in mice , 2006, Journal of gastroenterology and hepatology.

[35]  M. Manns,et al.  Elevation of Nepsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. , 2006, Clinical biochemistry.

[36]  A. D'Angelo,et al.  Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. , 2005, Archives of neurology.

[37]  H. Kaneto,et al.  Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. , 2005, Diabetes care.

[38]  K. Tsuneyama,et al.  Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs , 2005, Modern Pathology.

[39]  A. D'Angelo,et al.  Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension , 2005, Journal of hypertension.

[40]  L. Morelli,et al.  Quality assurance, efficiency indicators and cost‐utility of the evaluation workup for liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[41]  T. Kislinger,et al.  RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-α and NF-κB , 2005, The Journal of experimental medicine.

[42]  J. Emond,et al.  Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice , 2004, Hepatology.

[43]  G. Jerums,et al.  Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. , 2003, Archives of biochemistry and biophysics.

[44]  P. Rogalla,et al.  Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? , 2003, Biochimica et biophysica acta.

[45]  J. Enghild,et al.  Regulation of receptor for advanced glycation end products during bleomycin-induced lung injury. , 2003, American journal of respiratory cell and molecular biology.

[46]  W. Langhans Role of the liver in the control of glucose‐lipid utilization and body weight , 2003, Current opinion in clinical nutrition and metabolic care.

[47]  S. Takasawa,et al.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.

[48]  A. Schmidt,et al.  RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease , 2002, Cellular and Molecular Life Sciences CMLS.

[49]  A. Heidland,et al.  Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. , 2002, Journal of hepatology.

[50]  R. Atkins,et al.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.

[51]  A. Gressner,et al.  Up‐regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts , 2001, Hepatology.

[52]  Z. Kmieć,et al.  Cooperation of Liver Cells in Health and Disease , 2001, Advances in Anatomy Embryology and Cell Biology.

[53]  A. Joly,et al.  Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. , 2001, Endocrinology.

[54]  A. Schmidt,et al.  The biology of the receptor for advanced glycation end products and its ligands. , 2000, Biochimica et biophysica acta.

[55]  K. Matsumoto,et al.  Endocytic uptake of advanced glycation end products by mouse liver sinusoidal endothelial cells is mediated by a scavenger receptor distinct from the macrophage scavenger receptor class A. , 2000, The Biochemical journal.

[56]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[57]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[58]  A. Schmidt,et al.  Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.

[59]  Yukiko Kurihara,et al.  A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection , 1997, Nature.

[60]  H. Sano,et al.  Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. , 1997, The Biochemical journal.

[61]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[62]  Gressner Am Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. , 1996 .

[63]  A. Schmidt,et al.  RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.

[64]  A. Gressner Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. , 1996, Kidney international. Supplement.

[65]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[66]  Richard Barnett,et al.  Diabetes mellitus. , 1993, The Medical journal of Australia.

[67]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[68]  M. Suthanthiran,et al.  Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins , 1991, The Journal of experimental medicine.

[69]  J. Spaan,et al.  Coronary circulation : from basic mechanisms to clinical implications , 1987 .